Inhibitor-protected amoxicillin with increased amoxicillin content and active ingredients ratio of 14:1: the use for treatment of community-acquired respiratory infections and ENT infections in children. Expert Council Resolution

Roman S. Kozlov , Alexander I. Sinopalnikov , Olga V. Zaitseva , Sergey K. Zyryanov , Elena P. Karpova , Elena Yu. Radzig , Svetlana V. Zaitseva , Evelina E. Lokshina , Olga U. Stetsyuk , Irina V. Andreeva

For citation:

Abstract

The meeting of Expert Council, which included representatives of leading Russian research and higher education medical institutions, took place in Moscow. The Council discussed approaches to therapy of respiratory tract infections and ENT infections in children considering the global increase in antimicrobial resistance of respiratory tract pathogens. Special attention was paid to the use of new dosage form of amoxicillin-clavulanate 14:1, as well as to defining the category of patients to whom it is advisable to prescribe the high-dose amoxicillin-clavulanate.

Key words: Expert Council, antibacterial therapy, antimicrobial resistance, community-acquired infections, respiratory tract infections, respiratory infections, amoxicillin-clavulanate, high-dose therapy, children.

References

1. World Health Organization. COVID-19 Clinical management: living guidance. 25.01.2021. www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1

2. Nori P, Cowman K, Chen V et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Control Hosp Epidemiol 2021; 42 (1): 84–8. DOI: 10.1017/ice.2020.368

3. Maleev V.V., Zaitsev A.A., Yakovlev S.V. et al. O primenenii antibakterial'noi terapii u patsientov s novoi koronavirusnoi infektsiei COVID-19. Sovmestnoe obrashchenie k vrachebnomu soobshchestvu Rossii. Russian Medical Journal; 17.10.2020. www.rmj.ru/news/o-primenenii-antibakterialnoy-terapii-u-patsientov-s-novoy-koronavirusnoy-infektsiey-covid-19/ (in Russian).

4. World Health Organization (WHO). Antimicrobial resistance: global report on surveillance 2014. www.who.int/antimicrobial-resistance/publications/surveillancereport/en/

5. Kuzmenkov A.Yu., Trushin I.V., Avramenko A.A. et al. AMRmap: an online platform for monitoring antibiotic resistance. Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19 (2): 84–90 (in Russian).

6. Baranov A.A., Namazova L.S., Tatochenko V.K. Pneumococcal infection and associated diseases – a serious problem of modern health care. Pediatric Pharmacology. 2008; 5 (1): 7–13 (in Russian).

7. Stetsyuk O.U., Andreeva I.V., Egorova O.A. Antibiotic resistance of the main ENT pathogens. Russian Medical Inquiry. 2019; 3 (9-2): 78–83 (in Russian).

8. Torumkuney D, Mayanskiy N, Edelstein M et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Russia. J Antimicrob Chemother 2018; 73 (suppl_5): v14–21. DOI: 10.1093/jac/dky065

9. Mayanskiy N, Kulichenko T, Alyabieva N et al. Changing serotype distribution and resistance patterns among pediatric nasopharyngeal pneumococci collected in Moscow, 2010-2017. Diagn Microbiol Infect Dis 2019; 94 (4): 385–90. DOI: 10.1016/j.diagmicrobio.2019. 02.010

10. Sader HS, Flamm RK, Streit JM et al. Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America. Int J Infect Dis 2018; 77: 82–6. DOI: 10.1016/j.ijid.2018.10.004

11. Tomic V, Dowzicky MJ. Regional and global antimicrobial susceptibility among isolates of Streptococcus pneumoniae and Haemophilus influenzae collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) from 2009 to 2012 and comparison with previous years of T.E.S.T. (2004–2008). Ann Clin Microbiol Antimicrob 2014; 13: 52. DOI: 10.1186/s12941-014-0052-2

12. Cherazard R, Epstein M, Doan TL et al. Antimicrobial Resistant Streptococcus pneumoniae: Prevalence, Mechanisms, and Clinical Implications. Am J Ther 2017; 24 (3): e361–9. DOI: 10.1097/MJT. 0000000000000551

13. Fong IW, Shlaes D, Drlica K, editors. Antimicrobial Resistance in the 21st Century. 2nd ed. Springer; 2018. DOI: 10.1007/978-3-319-78538-7_2

14. Tadesse BT, Ashley EA, Ongarello S et al. Antimicrobial resistance in Africa: a systematic review. BMC Infect Dis 2017; 17 (1): 616. DOI: 10.1186/s12879-017-2713-1

15. Ho J, Ip M. Antibiotic-Resistant Community-Acquired Bacterial Pneumonia. Infect Dis Clin North Am 2019; 33 (4): 1087–103. DOI: 10.1016/j.idc.2019.07.002

16. Hagiwara E, Baba T, Shinohara T et al. Ten-Year Trends and Clinical Relevance of the Antimicrobial Resistance Genotype in Respiratory Isolates of Streptococcus pneumoniae. Chemotherapy 2017; 62 (4): 256–61. DOI: 10.1159/000470828

17. Wang X, Cong Z, Huang W, Li C. Molecular characterization of Streptococcus pneumoniae isolated from pediatric patients in Shanghai, China. Pediatr Pulmonol 2020; 55 (8): 2135–41. DOI: 10.1002/ppul.24877

18. Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2019. www.ecdc.europa.eu/sites/default/ files/documents/surveillance-antimicrobial-resistance-Europe-2019.pdf

19. Zharkova L.P., Stetsyuk O.U., Andreeva I.V., Yegorova O.A. Modern trends for use of protected aminopenicillins in the treatment of respiratory tract infections in ambulatory practice. Farmateka. 2011; 4 (217): 8–16 (in Russian).

20. Stratton CW. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 2003; 9 (1): 10–6. DOI: 10.3201/eid0901.020172

21. Svistushkin V.M., Andreeva I.V., Stetsiouk O.U. Review of current guidelines on the management of pediatric patients with acute bacterial rhinosinusitis. Clinical Microbiology and Antimicrobial Chemotherapy. 2012; 14 (3): 176–90 (in Russian).

22. Dagan R. Achieving bacterial eradication using pharmacokinetic/ pharmacodynamic principles. Int J Infect Dis 2003; 7 Suppl 1: S21–6. DOI: 10.1016/s1201-9712(03)90067-1

23. Dagan R. The use of pharmacokinetic/pharmacodynamic principles to predict clinical outcome in paediatric acute otitis media. Int J Antimicrob Agents 2007; 30 Suppl 2: S127–30. DOI: 10.1016/j.ijantimicag.2007.07.039

24. Craig WA. Overview of newer antimicrobial formulations for overcoming pneumococcal resistance. Am J Med 2004; 117 Suppl 3A: 16S–22S. DOI: 10.1016/j.amjmed.2004.07.004

25. Strachunskiy L.S., Belousov Yu.B., Kozlov S.N., editors. Prakticheskoe rukovodstvo po antiinfektsionnoi khimioterapii. Smolensk: MAKMAKH, 2007 (in Russian).

26. Lobzin Yu.V., Briko N.I., Kozlov R.S. et al. Rezoliutsiia Ekspertnogo soveta "Printsipy ratsional'noi antibiotikoterapii respiratornykh infektsii u detei. Sokhranim antibiotiki dlia budushchikh pokolenii". 31 marta 2018 g., Moskva. Pediatrics. Consilium Medicum. 2018; (3): 10–5. DOI: 10.26442/2413-8460_2018.3.10-15 (in Russian).

27. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Amoksitsillin Dispertab® (tabletki dispergiruemye 125 mg, 250 mg, 500 mg, 1000 mg). Proizvoditel' – AVVA RUS OAO, nomer registratsionnogo udostovereniia LP-006567-131120 (in Russian).

28. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Amoksitsillin (kapsuly 250 mg). Proizvoditel' – AVVA RUS OAO, nomer registratsionnogo udostovereniia LS-000409-270912 (in Russian).

29. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Amoksitsillin (kapsuly 250 i 500 mg). Proizvoditel' – Khemofarm A.D. (Serbiia), nomer registratsionnogo udostovereniia P N011641/01-270919 (in Russian).

30. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata Amoksiklav (poroshok dlia prigotovleniia suspenzii dlia priema vnutr' 600 mg + 42,9 mg / 5 ml). Proizvoditel' – Sandoz d.d., nomer registratsionnogo udostovereniia LP-006516-161020 (in Russian).

31. Bottenfield GW, Burch DJ, Hedrick JA et al. Safety and tolerability of a new formulation (90 mg/kg/day divided every 12 h) of amoxicillin/clavulanate (Augmentin) in the empiric treatment of pediatric acute otitis media caused by drug-resistant Streptococcus pneumoniae. Pediatr Infect Dis J 1998; 17 (10): 963–8. DOI: 10.1097/ 00006454-199810000-00041

32. Dagan R, Hoberman A, Johnson C et al. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J 2001; 20 (9): 829–37. DOI: 10.1097/ 00006454-200109000-00002

33. Hoberman A, Dagan R, Leibovitz E et al. Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children. Pediatr Infect Dis J 2005; 24 (6): 525–32. DOI: 10.1097/01.inf.0000164794.50281.1a

34. Block SL, Schmier JK, Notario GF et al. Efficacy, tolerability, and parent reported outcomes for cefdinir vs. high-dose amoxicillin/clavulanate oral suspension for acute otitis media in young children. Curr Med Res Opin 2006; 22 (9): 1839–47. DOI: 10.1185/030079906 X132406

35. Sher L, Arguedas A, Husseman M et al. Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children. Pediatr Infect Dis J 2005; 24 (4): 301–8. DOI: 10.1097/01.inf.0000157084.35865.ba

36. Wald ER, Nash D, Eickhoff J. Effectiveness of amoxicillin/clavulanate potassium in the treatment of acute bacterial sinusitis in children. Pediatrics 2009; 124 (1): 9–15. DOI: 10.1542/peds.2008-2902

37. Poachanukoon O, Kitcharoensakkul M. Efficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trial. Clin Ther 2008; 30 (10): 1870–9. DOI: 10.1016/j.clinthera.2008.10.001.

38. Chow AW, Benninger MS, Brook I et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012; 54 (8): e72–112. DOI: 10.1093/cid/cir1043

39. Pavez D, Pérez R, Cofré J, Rodríguez J. Recomendaciones para el diagnóstico y tratamiento antimicrobiano de la rinosinusitis aguda bacteriana en pediatría [Recommendations for diagnosis and antimicrobial treatment of acute bacterial rhinosinusitis in pediatrics]. Rev Chilena Infectol 2019; 36 (1): 78–82 (in Spanish). DOI: 10.4067/ S0716-10182019000100078

40. Leung AK, Hon KL, Chu WC. Acute bacterial sinusitis in children: an updated review. Drugs Context 2020; 9: 2020-9-3. DOI: 10.7573/dic.2020-9-3

41. Lieberthal AS, Carroll AE, Chonmaitree T et al. The diagnosis and management of acute otitis media. Pediatrics 2013; 131 (3) :e964–99. DOI: 10.1542/peds.2012-3488. Erratum in: Pediatrics 2014; 133 (2): 346.

42. Wald ER, Applegate KE, Bordley C et al. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. Pediatrics 2013; 132 (1): e262–80. DOI: 10.1542/peds.2013-1071

43. Bradley JS, Byington CL, Shah SS et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53 (7): e25–76. DOI: 10.1093/cid/cir531

44. Grant GB, Campbell H, Dowell SF et al. Recommendations for treatment of childhood non-severe pneumonia. Lancet Infect Dis 2009; 9 (3): 185–96. DOI: 10.1016/S1473-3099(09)70044-1

45. Rossiiskoe respiratornoe obshchestvo, Mezhregional'noe pediatricheskoe respiratornoe obshchestvo, Federatsiia pediatrov stran SNG, Moskovskoe obshchestvo detskikh vrachei. Vnebol'nichnaia pnevmoniia u detei: klinicheskie rekomendatsii. Moscow: Original-maket, 2015 (in Russian).

For citation:Kozlov R.S., Sinopalnikov A.I., Zaitseva O.V., Zyryanov S.K., Karpova E.P., Radzig E.Yu., Zaitseva S.V., Lokshina E.E., Stetsyuk O.U., Andreeva I.V. Inhibitor-protected amoxicillin with increased amoxicillin content and active ingredients ratio of 14:1: the use for treatment of community-acquired respiratory infections and ENT infections in children. Expert Council Resolution. Clinical review for general practice. 2021; 2: 6–14. DOI: 10.47407/kr2021.2.1.00036

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice